Previous Close | 0.8911 |
Open | 0.9578 |
Bid | 0.9500 x 1800 |
Ask | 1.0100 x 1400 |
Day's Range | 0.9500 - 1.0100 |
52 Week Range | 0.8800 - 8.3850 |
Volume | |
Avg. Volume | 169,979 |
Market Cap | 98.122M |
Beta (5Y Monthly) | 1.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9650 |
Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for SMMT
Summit Provides Preliminary Update on Financial PositionMenlo Park, California, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on August 8, 2022 (the “Expiration Date”). Importantly, for stockholders whose shares of our common stock are held in a brokerage account or are otherwise not registered directly with t
Bob Duggan Remains Chairman of the Board of Directors and CEOMenlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer & President, effective immediately. Dr. Zanganeh was formerly the Company’s Chief Operating Officer, having served in that capacity since she joined the Company as an employee in November 2020, and remains a member of the Company’s Board of Directo
Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the Company’s common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 pm Eastern Time on August 8, 2022, the expiration date (the “Expiration Date”). Pursuant to the rights offering, Summit is distributing, at no charge to the holders of its common stock